FindTrial
Sign In

Median effective plasma concentration of remifentanil inhibiting cardiovascular response to skull-pin placement when combined with propofol in female patients undergoing neurosurgery

Median effective plasma concentration of remifentanil inhibiting cardiovascular response to skull-pin placement when combined with propofol in female patients undergoing neurosurgery

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16009859
Enrollment
Unknown
Registered
2016-11-14
Start date
2016-11-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurosurgery

Interventions

study group:propofol and remifentanil

Sponsors

Southern District of Anhui Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Neurosurgical female patients with skull pin fixation; 2. Aged 20-60 years; 3. BMI 18-30 kg/m2; 4. ASA physical status I-II.

Exclusion criteria

Exclusion criteria: 1. History of cardiac, pulmonary, liver or renal disease; 2. Drug or alcohol abuse; 3. Current use of any vasoactive medications; 4. Recent use of any medications known to affect sympathetic adrenergic response.

Design outcomes

Primary

MeasureTime frame
Median effective plasma concentration of remifentanil inhibiting cardiovascular response to skull-pin placement when combined with propofol in female patients undergoing neurosurgery;—

Secondary

MeasureTime frame
Mean arterial pressure;Heart rate;—

Countries

China

Contacts

Public ContactLi Juan

Southern District of Anhui Provincial Hospital

huamuzi1999@126.com+86 13956005465

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026